TScan Therapeutics annual debt-to-assets ratio
2020
2021
2022
2023
2024
2025
TScan Therapeutics Debt-to-Assets Ratio Growth & History (TCRX)
TScan Therapeutics's debt-to-assets ratio was 0.41 for fiscal 2025.
View full TScan Therapeutics company overviewTScan Therapeutics annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.41 | 0.15 | +56.81% |
| 2024 | 2024-12-31 | 0.26 | −0.08 | −22.74% |
| 2023 | 2023-12-31 | 0.34 | −0.09 | −21.36% |
| 2022 | 2022-12-31 | 0.43 | 0.40 | +1244.37% |
| 2021 | 2021-12-31 | 0.03 | −0.12 | −78.51% |
| 2020 | 2020-12-31 | 0.15 | — | — |
TScan Therapeutics quarterly debt-to-assets ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.53 | 0.21 | +63.68% |
| Q1 2026 | 2026-03-31 | 0.46 | 0.17 | +57.08% |
| Q4 2025 | 2025-12-31 | 0.41 | 0.15 | +56.81% |
| Q3 2025 | 2025-09-30 | 0.36 | 0.11 | +40.46% |
| Q2 2025 | 2025-06-30 | 0.32 | 0.08 | +33.32% |
| Q1 2025 | 2025-03-31 | 0.29 | −0.09 | −23.45% |
| Q4 2024 | 2024-12-31 | 0.26 | −0.08 | −22.74% |
| Q3 2024 | 2024-09-30 | 0.26 | −0.04 | −13.03% |
| Q2 2024 | 2024-06-30 | 0.24 | −0.03 | −12.25% |
| Q1 2024 | 2024-03-31 | 0.38 | −0.11 | −22.48% |
| Q4 2023 | 2023-12-31 | 0.34 | −0.09 | −21.36% |
| Q3 2023 | 2023-09-30 | 0.30 | 0.09 | +45.70% |
| Q2 2023 | 2023-06-30 | 0.28 | 0.24 | +704.95% |
| Q1 2023 | 2023-03-31 | 0.49 | 0.46 | +1364.24% |
| Q4 2022 | 2022-12-31 | 0.43 | 0.40 | +1244.37% |
| Q3 2022 | 2022-09-30 | 0.20 | 0.17 | +554.81% |
| Q2 2022 | 2022-06-30 | 0.03 | −0.02 | −34.11% |
| Q1 2022 | 2022-03-31 | 0.03 | — | — |
| Q4 2021 | 2021-12-31 | 0.03 | −0.12 | −78.51% |
| Q3 2021 | 2021-09-30 | 0.03 | — | — |
| Q2 2021 | 2021-06-30 | 0.05 | — | — |
| Q4 2020 | 2020-12-31 | 0.15 | — | — |
TScan Therapeutics debt-to-assets ratio trends
Over the last five fiscal years, TScan Therapeutics's debt-to-assets ratio increased from 0.15 to 0.41, a change of 0.26. The latest reported quarter, Q2 2026, shows 0.53.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review TScan Therapeutics source filings ↗